Share This Page
Investigational Drug Information for Imexon
✉ Email this page to a colleague
What is the drug development status for Imexon?
Imexon is an investigational drug.
There have been 8 clinical trials for Imexon.
The most recent clinical trial was a Phase 2 trial, which was initiated on May 1st 2011.
The most common disease conditions in clinical trials are Carcinoma, Non-Small-Cell Lung, Lymphoma, Large B-Cell, Diffuse, and Breast Neoplasms. The leading clinical trial sponsors are AmpliMed Corporation, University of Arizona, and University of Rochester.
Summary for Imexon
| US Patents | 0 |
| International Patents | 0 |
| US Patent Applications | 741 |
| WIPO Patent Applications | 281 |
| Japanese Patent Applications | 146 |
| Clinical Trial Progress | Phase 2 (2011-05-01) |
| Vendors | 16 |
Recent Clinical Trials for Imexon
| Title | Sponsor | Phase |
|---|---|---|
| Imexon for Relapsed Follicular and Aggressive Lymphomas | University of Arizona | Phase 2 |
| Imexon for Relapsed Follicular and Aggressive Lymphomas | University of Rochester | Phase 2 |
| A Safety and Efficacy Trial of Amplimexon Plus Taxotere in Metastatic Non-Small Cell Lung Cancer | AmpliMed Corporation | Phase 2 |
Clinical Trial Summary for Imexon
Top disease conditions for Imexon
Top clinical trial sponsors for Imexon
US Patents for Imexon
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
Imexon Development Update, Patent Status, FDA Pathway, and Market Projection
Imexon is an investigational small-molecule anticancer agent with no FDA approval, no established commercial market, and no confirmed active late-stage development program. Historical clinical work evaluated imexon primarily in multiple myeloma and pancreatic cancer. Public development activity appears to have stopped at early- or mid-stage clinical testing. On that basis, the probability of a commercial launch is currently very low, and a reliable revenue forecast is not supportable.
What is imexon and how does it work?
Imexon is an investigational cytotoxic compound also described as a pro-oxidant anticancer agent. Its proposed mechanism involves depletion of intracellular glutathione, generation of oxidative stress, disruption of mitochondrial function, and induction of apoptosis in malignant cells.
The compound was studied as a potential treatment for hematologic malignancies and solid tumors, including:
- Multiple myeloma
- Pancreatic cancer
- Other advanced cancers in early clinical studies
Imexon is not an antibody, cell therapy, gene therapy, or biosimilar. Biosimilar competition is therefore not relevant. Any future competition would come from small-molecule generics or from newer branded therapies in the same treatment settings.
What is the current development status of imexon?
The current development status is inactive or discontinued based on the absence of a recent late-stage program, FDA approval, or commercial sponsor activity in the principal public drug-development sources.
| Development element | Current assessment |
|---|---|
| Drug type | Investigational small-molecule anticancer agent |
| Primary mechanism | Pro-oxidant and glutathione-depleting activity |
| Principal studied indications | Multiple myeloma and pancreatic cancer |
| FDA approval | None identified |
| NDA or BLA | None identified |
| Commercial product | None |
| Phase III development | No confirmed active program |
| Marketed revenue | None |
| Biosimilar exposure | Not applicable |
| Current commercial status | No established commercial development |
Historical studies evaluated imexon alone and in combination with other agents, including chemotherapy and dexamethasone-based regimens. The available clinical record does not indicate that these studies produced the efficacy, safety, or strategic positioning needed to support a registrational program.
The most relevant development signal was the transition from laboratory work into early human testing. The program did not progress into a visible pivotal-development stage. That distinction is material: an oncology candidate without an active Phase III trial, regulatory filing, or well-capitalized sponsor has a materially lower probability of reaching the market.
What clinical results were reported for imexon?
Clinical evidence for imexon has been limited and early-stage. Studies in multiple myeloma investigated imexon in patients with relapsed or refractory disease, including combination use with dexamethasone. Separate work evaluated imexon with gemcitabine in advanced pancreatic cancer.
Reported findings generally indicated biological activity but limited evidence of durable, practice-changing efficacy. The clinical program faced several constraints:
- Patients were heavily pretreated and had advanced disease.
- The studies were small and not designed to establish definitive comparative efficacy.
- The clinical benefit did not clearly exceed established treatment alternatives.
- Development did not advance to a confirmatory randomized program.
The available evidence is therefore insufficient to establish imexon as an effective standard treatment for either multiple myeloma or pancreatic cancer.
What is the FDA regulatory status of imexon?
Imexon has no identified FDA approval and no listed U.S. commercial label. It does not have an Orange Book reference product, approved generic equivalents, or FDA-recognized regulatory exclusivity.
| FDA status category | Imexon status |
|---|---|
| Approved active ingredient | No |
| Approved indication | No |
| New Drug Application | No publicly identified approved NDA |
| Orange Book listing | None identified |
| Paragraph IV litigation | None identified |
| New chemical entity exclusivity | Not granted because no approval has been identified |
| Orphan-drug approval | None identified |
| Market exclusivity | None currently active |
Because imexon has not reached approval, the standard Hatch-Waxman sequence does not apply. There is no reference listed drug against which an ANDA applicant could file a Paragraph IV certification. A future sponsor would first need to obtain approval for imexon itself before any conventional generic-entry framework could arise.
Sources including FDA Drugs@FDA, the Orange Book, ClinicalTrials.gov, PubChem, and National Cancer Institute materials do not identify a marketed imexon product or an active regulatory review.
What patents protect imexon?
Publicly available development information does not establish a currently enforceable, commercially relevant patent estate for imexon.
Historical patent protection may have covered one or more of the following:
- The imexon chemical entity
- Synthetic methods
- Pharmaceutical compositions
- Combination use with chemotherapy
- Methods of treating multiple myeloma
- Methods of treating pancreatic cancer
- Pro-oxidant or glutathione-depletion applications
The absence of an approved product makes patent analysis less commercially significant than it would be for an active branded drug. Patent term may have expired, may be approaching expiration, or may have become irrelevant because no sponsor is pursuing approval.
A definitive patent assessment would require a current family-level review of U.S., European, and international records, including continuity data, terminal disclaimers, maintenance fees, patent-term adjustment, patent-term extension, and assignment history. Public sources do not support a reliable claim that a live, blocking patent currently protects a commercial imexon product.
How many patents cover imexon?
No reliable current count of commercially material, unexpired imexon patents can be established from the public development record. Patent families may exist, but a raw publication count would overstate protection because the count could include abandoned applications, foreign counterparts, expired claims, continuations, and patents assigned to entities no longer developing the compound.
Are formulation patents important for imexon?
Formulation patents could have covered injectable or oral dosage forms, stability, excipients, dosing schedules, or combination regimens. No approved formulation has created a recognized Orange Book-listed formulation patent.
For a future restart, formulation protection would be relevant only if the sponsor could demonstrate a meaningful improvement in bioavailability, tolerability, dosing convenience, or combination delivery. A basic formulation claim would face a higher invalidity and design-around risk than a clinically differentiated delivery system.
Are there Paragraph IV challenges or imexon patent lawsuits?
No material Paragraph IV challenge, ANDA litigation, or Hatch-Waxman settlement involving imexon has been identified.
That outcome follows from the regulatory status. Imexon has no approved reference product and no Orange Book-listed patents. Patent disputes could still arise under ordinary federal patent law if a company attempted commercial development, but the public record does not show an active imexon patent-litigation campaign.
There is also no confirmed public settlement agreement involving a generic manufacturer and an imexon sponsor.
Which companies are developing or challenging imexon?
No active commercial developer or generic challenger has been clearly identified in the current public record.
Historical development involved academic oncology investigators and commercial or research sponsors associated with early clinical testing. The program has not produced a visible current licensing transaction, co-development agreement, or acquisition announcement that would indicate renewed investment.
| Commercial activity | Current assessment |
|---|---|
| Active originator sponsor | Not confirmed |
| Current licensee | Not confirmed |
| Co-development agreement | None identified |
| Generic challenger | None |
| Biosimilar challenger | Not applicable |
| Recent acquisition tied to imexon | None identified |
| Active clinical recruiting | Not confirmed |
The lack of an identifiable sponsor is a direct commercial risk. A development restart would require ownership clarification, freedom-to-operate diligence, renewed toxicology and manufacturing work, and a new clinical strategy.
How does imexon compare with competing cancer drugs?
Imexon was evaluated in settings where treatment standards have changed substantially since its early studies.
Multiple myeloma
Multiple myeloma treatment now includes proteasome inhibitors, immunomodulatory drugs, anti-CD38 antibodies, BCMA-directed therapies, bispecific antibodies, and cellular therapies. These products have established clinical positioning, regulatory approval, commercial infrastructure, and physician familiarity.
Imexon would enter a highly competitive relapsed/refractory market without demonstrated superiority, a differentiated biomarker strategy, or a validated combination advantage. Its most plausible positioning would be a niche salvage regimen, but that market is crowded and increasingly dominated by targeted and immune-based approaches.
Pancreatic cancer
Pancreatic cancer treatment includes gemcitabine-based regimens, modified FOLFIRINOX, nanoliposomal irinotecan combinations, and selected biomarker-directed therapies. Imexon would need to demonstrate meaningful survival or quality-of-life improvement against established regimens.
Its historical combination approach with gemcitabine would not, by itself, create a strong commercial position. A new trial would need a clear mechanistic rationale, patient-selection strategy, or biomarker that identifies a responsive subgroup.
What is the market projection for imexon?
The near-term market projection is effectively zero because imexon has no approved indication, no commercial supply, and no active late-stage program.
A restart scenario would still produce a modest risk-adjusted commercial outlook. The principal assumptions are:
- A new sponsor would need to reacquire or validate development rights.
- Clinical development would likely require a new dose, safety, and efficacy package.
- A pivotal oncology program could require several years and substantial capital.
- The competitive standard of care has advanced since the original trials.
- No validated predictive biomarker has established a concentrated responder population.
- Patent and regulatory exclusivity may be weak or unavailable.
Scenario-based commercial outlook
| Scenario | Development outcome | Commercial implication |
|---|---|---|
| Base case | Program remains inactive | No product revenue |
| Restart without strong biomarker | Early-stage redevelopment but weak differentiation | Low probability of approval; limited peak sales |
| Restart with validated biomarker | Targeted development in a defined subgroup | Potential niche product, subject to clinical success |
| Successful approval in multiple myeloma | Entry into crowded relapsed disease market | Moderate niche opportunity, significant pricing pressure |
| Successful approval in pancreatic cancer | Use in a high-need setting | Commercial value depends on survival benefit and tolerability |
A conventional probability-adjusted forecast should assign negligible near-term sales because there is no active Phase III program or regulatory submission. An unadjusted peak-sales estimate would be speculative and could mislead investment or licensing decisions.
How strong is the imexon patent and commercial estate?
The estate appears weak from a current commercial perspective, even if historical composition-of-matter or use patents were once filed.
Patent strength depends on remaining term, claim scope, ownership, validity, enforceability, and the existence of a development program. Imexon lacks the commercial anchors that usually increase estate value:
- No approved product
- No Orange Book listing
- No pediatric exclusivity
- No regulatory exclusivity
- No active commercial sponsor
- No visible pivotal trial
- No demonstrated best-in-class efficacy
- No established manufacturing franchise
The main residual value would be scientific or strategic. A buyer might assess imexon as a repurposing or combination candidate rather than as a protected near-term commercial asset.
What manufacturing and intellectual-property barriers exist?
Manufacturing risk is likely manageable compared with biologics or cell therapies because imexon is a small molecule. The greater risks are development validation, formulation reproducibility, impurity control, scale-up, and long-term supply economics.
A future sponsor would need to establish:
- A reproducible synthetic route
- Controlled impurity specifications
- Stable drug substance and drug product
- A clinically acceptable dosage form
- Good Manufacturing Practice production
- Updated pharmacology and toxicology documentation
- A defensible freedom-to-operate position
Small-molecule manufacturing does not eliminate intellectual-property risk. If composition-of-matter protection has expired, the sponsor may need to rely on formulation, method-of-use, dosing, combination, or process patents. Those rights generally provide narrower protection than a live composition-of-matter patent.
Key Takeaways
- Imexon is an investigational anticancer small molecule with no FDA approval.
- Historical studies focused on multiple myeloma and pancreatic cancer.
- The program did not progress to a confirmed pivotal or commercial stage.
- No Orange Book listing, approved reference product, Paragraph IV challenge, or generic litigation has been identified.
- No active developer, licensee, or commercial sponsor is clearly established.
- Biosimilar risk does not apply because imexon is a small molecule.
- The current revenue outlook is zero.
- Any future value depends on a development restart, stronger clinical differentiation, and confirmation of surviving patent or regulatory rights.
- The most credible commercial opportunity would be a narrowly defined oncology niche, not a broad-market launch.
FAQs About Imexon
Is imexon approved by the FDA?
No. Imexon has no identified FDA approval, commercial label, or Orange Book listing.
What cancers was imexon studied to treat?
Clinical studies evaluated imexon mainly in multiple myeloma and advanced pancreatic cancer. Early research also considered broader anticancer applications.
Can a generic company launch imexon?
There is no current generic launch pathway because imexon has no approved reference product. A company would need regulatory approval before a conventional generic market could develop.
Does imexon have biosimilar competition?
No. Biosimilar rules apply to biological products. Imexon is a small-molecule compound.
Is imexon still a viable licensing opportunity?
The asset has high development risk and no visible near-term commercial revenue. Its licensing value would depend on verified ownership, surviving patents, reproducible manufacturing, updated clinical rationale, and evidence of a biomarker-defined responder population.
References
-
ClinicalTrials.gov. (n.d.). Search results for imexon clinical studies. U.S. National Library of Medicine. https://clinicaltrials.gov/
-
Food and Drug Administration. (n.d.). Drugs@FDA: FDA-approved drugs. U.S. Department of Health and Human Services. https://www.accessdata.fda.gov/scripts/cder/daf/
-
Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. U.S. Department of Health and Human Services. https://www.accessdata.fda.gov/scripts/cder/ob/
-
National Cancer Institute. (n.d.). Imexon. NCI Drug Dictionary. https://www.cancer.gov/publications/dictionaries/cancer-drug
-
National Center for Biotechnology Information. (n.d.). PubChem compound database: Imexon. U.S. National Library of Medicine. https://pubchem.ncbi.nlm.nih.gov/
-
National Library of Medicine. (n.d.). DailyMed. U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/
More… ↓
